MC10 is a technology company.
MC10 develops wearable sensor technology for clinical trials, enabling the collection of objective data alongside patient-reported outcomes to enhance trial efficiency and patient engagement.
MC10 has raised $41.0M across 5 funding rounds.
MC10 has raised $41.0M in total across 5 funding rounds.
MC10 has raised $41.0M in total across 5 funding rounds.
MC10's investors include Aberdare Ventures, Braemar Energy Ventures, Breakthrough Energy Ventures, GE Ventures, MassMutual Ventures, Forest Baskett, Greg Papadopoulos, Jeff Immelt, Osage University Partners, Jaffray Woodriff.
MC10 is a technology company specializing in flexible, conformal electronics for wearable health sensors, primarily targeting clinical research and patient monitoring. It developed the BioStamp nPoint system, which integrates thin, stretchable sensors with analytics software to capture physiological data like movement and biometrics from home or clinical settings, solving the problem of unobtrusive, high-fidelity data collection beyond rigid wearables[1][2][3][4]. Serving biopharma, MedTech, academic organizations, and clinical trial sponsors, MC10 addressed limitations in traditional wearables by enabling seamless skin integration for applications in movement disorders, multiple sclerosis trials, and digital biomarkers, with strong growth evidenced by $61.2M in funding and partnerships like AbbVie and UCB before its 2020 acquisition[1][2][3].
Founded in 2008 in Lexington, Massachusetts, MC10 emerged from research by co-founder John Rogers, a pioneer in bridging electronics with the human body through ultra-thin, flexible materials[2][3]. Co-founders Ben Schlatka (CEO) and Roozbeh Ghaffari (VP of Technology) drove the vision, initially exploring sports medicine before pivoting to broader healthcare in 2015-2016, releasing its first product amid clinical validations at Mass General, University of Rochester, and University of Arizona[1][3]. Early traction included a $10M Series C in 2012 with Medtronic as an investor, partnerships like UCB for disease management, and AbbVie's use in MS trials by 2019, culminating in Medidata's 2020 acquisition of its digital biomarker business to enhance clinical trial platforms[1][2][3].
MC10 rides the wearable tech and digital health boom, particularly electronic skin and remote monitoring trends projected to reach $44.6B by 2032 at 21.4% CAGR, fueled by demand for patient-centric clinical trials amid personalized medicine[2]. Its timing aligned with post-2015 shifts from fitness trackers to validated medical devices, capitalizing on AI, big data, and post-COVID telehealth needs for real-time biomarkers[1][2][3]. By influencing ecosystem standards—via patents, pharma integrations, and Medidata's platform—MC10 advances therapy development, reducing trial costs and improving outcomes in neuro, MS, and beyond[1].
Post-2020 acquisition, MC10's tech thrives within Medidata, powering data-driven clinical platforms amid AI wearables growth; expect expanded electronic skin applications in trials, driven by regulatory nods and market expansion[1][2]. Trends like multimodal sensors and edge AI will amplify its role, potentially evolving influence through Dassault's 3DEXPERIENCE for end-to-end life sciences[1]. As a pioneer in conformal health tech, MC10 exemplifies how flexible electronics unlock human-data interfaces, transforming rigid monitoring into seamless health insights.
MC10 has raised $41.0M across 5 funding rounds. Most recently, it raised $10.0M Venture Round in August 2018.